Status:
COMPLETED
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
Detailed Description
Lung cancer is a major cause of morbidity and mortality, which is the rapidest increased type of cancer in China with over 5 times incidence rate increase during the past 30 years. Tyrosine kinase inh...
Eligibility Criteria
Inclusion
- Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).
- Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment.
- Measurable, evaluable disease outside of a radiation port.
Exclusion
- Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01465243
Start Date
September 1 2011
End Date
February 1 2014
Last Update
February 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
307 Hospital of People's Liberation Army（PLA）
Beijing, Beijing Municipality, China, 100071